The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Regulation Of Neural Progenitor Cell Self-renewal By The RNA-binding Protein ZFP36L1 During Development And Disease
Funder
National Health and Medical Research Council
Funding Amount
$345,401.00
Summary
The timely differentiation of neural stem cells is critical during development, and the unrestrained proliferation of neural stem cells in the adult can lead to deadly brain cancers such as glioma. At present our understanding of the key molecules that regulate neural stem cell behaviour during these processes remains limited. In this proposal we will investigate the molecular determinants underpinning neural stem cell biology, both within the developing brain, and within glioma.
Selective Isolation And In Vivo Properties Of Dopamine Neurons Generated From Embryonic Stem Cells.
Funder
National Health and Medical Research Council
Funding Amount
$505,389.00
Summary
This research aims to develop a procedure that allows for the safe and effective use of stem cells as a therapy for Parkinson’s disease. It is based on the concept that new dopamine neurons, generated from stem cells, can be implanted into the brain of the patients in order to replace those lost to the disease, thereby improving motor function.
Using Stem Cells And Bioengineered Scaffolds To Promote Regeneration Following Necrotic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$710,857.00
Summary
A number of injuries, including stroke, result in tissue loss. Consequently promoting repair will require restoration of tissue structure, replacement cells and a supportive environment to promote integration of these new cells. This study will engineer and develop novel scaffolds that can replace tissue whilst additionally providing physical and chemical support for newly implanted stem cells. This work will be conducted in an animal model of stroke.
Standardising Protocols For The Differentiation And Integration Of Human Pluripotent Stem Cell-derived Neural Transplants In Parkinson's Disease
Funder
National Health and Medical Research Council
Funding Amount
$987,664.00
Summary
Clinical trials have shown that transplanting dopamine neurons (specific nerve cells) into the brain of Parkinson’s disease patients can improve symptoms. Trials use fetal tissue for implantation, which is unsustainable and highly variable. This proposal will examine stem cells as an alternative. We will establish a reliable protocol to instruct human stem cells to become dopamine neurons, develop methods to select these cells and, examine the integration of these transplanted cells in the brain
Brain Repair Following Stroke: The Role Of Npas4, A Neural-specific Transcription Factor
Funder
National Health and Medical Research Council
Funding Amount
$611,053.00
Summary
Stroke is the #1 cause of adult disability in Australia and #2 cause of death. About 60,000 Australians suffer a stroke each year while about 250,000 live with the disabilities of stroke, costing over $2B/year. The Queen Elizabeth Hospital and University of Adelaide will study why the Npas4 gene switches on after stroke and the role it plays in brain repair. Future health benefits may be tests to help improve stroke outcome in patients and therapy to decrease loss of brain cells after stroke.
Reprogramming is the conversion of any cell into induced pluripotent stem cells (iPSC). iPSC carry immense clinical potential as they are pluripotent and can hence form any cell of the human body, however, they can also form tumours. We have identified a cell type during reprogramming which is pluripotent but cannot form tumours. It is the aim of this project to determine the molecular differences between iPSC and this cell type in order to facilitate the delivery of cell replacement therapies.
A Simple Method To Improve Stem Cell Transplant Therapy
Funder
National Health and Medical Research Council
Funding Amount
$831,652.00
Summary
Despite the success of hematopoietic stem cell transplantation and years of promise, almost all other stem cell therapies are considered experimental and remain in preclinical or early-phase clinical testing. This study aims to improve the efficiency of stem cell transplantation by manipulating cellular metabolism prior to transplantation, if effective these results may offer hope to patients suffering from a broad range of disorders.
The Role Of Oligodendrocytes In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$625,292.00
Summary
Dementia affects 35.6 million people world-wide; this number is projected to double every 20 years. Frontotemporal dementia (FTD) is the second most common type and has been found to have similar cause and pathology to common neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). We ultimately require treatments to slow, stop and repair the damaged brain of FTD patients and this is only possible by understanding the mechanisms involved in the onset and progression of disease.
Generating Haematopoietic Stem Cells From Human Pluripotent Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$872,215.00
Summary
Blood stem cell transplantation is a vital therapy for patients with leukaemia following chemotherapy or for patients with bone marrow failure. Because many patients lack a donor, there is a need for an alternate source of stem cells. Using a new approach that we have developed, our laboratories will make blood stem cells from human pluripotent stem cells that will treat patients needing a transplant.